Use of asprosin and subfatin for differential diagnosis of serous ovarian tumors
| dc.contributor.author | Mirzaoglu, Miyase | |
| dc.contributor.author | Yavuzkir, Seyda | |
| dc.contributor.author | Mirzaoglu, Cetin | |
| dc.contributor.author | Yurt, Nurdan | |
| dc.contributor.author | Dagli, Adile Ferda | |
| dc.contributor.author | Yildirim, Sena Ozcan | |
| dc.contributor.author | Aydin, Suleyman | |
| dc.date.accessioned | 2026-08-12T17:07:03Z | |
| dc.date.issued | 2023 | |
| dc.department | Fırat Üniversitesi | |
| dc.description.abstract | Asprosin (ASP) and subfatin are hormones that regulate glucose metabolism. The role of ASP and subfatin in serous ovarian tumors has not been investigated. We investigated the expression of subfatin and asprosin in 30 serous benign, 30 serous borderline, 30 malignant and 30 control ovarian tissues. We investigated ASP and subfatin immunoreactivity and quantification was achieved using an ELISA method. ASP and subfatin were localized in the epithelial parts of normal ovarian tissues; however, in cancer tissues, immunoreactivity was detected in the parenchymal areas. Biochemical analysis of ovarian tissues revealed significantly decreased ASP and subfatin compared to the control. We propose that ASP and subfatin are promising candidates for biomarkers to distinguish serous benign, serous borderline and malignant ovarian cancers. | |
| dc.description.sponsorship | Scientific Research and Support Unit of Firat University [TF.19.29] | |
| dc.description.sponsorship | We thank the Scientific Research and Support Unit of Firat University for their financial support for the conduct of the study with the protocol number TF.19.29. | |
| dc.identifier.doi | 10.1080/10520295.2022.2135763 | |
| dc.identifier.endpage | 146 | |
| dc.identifier.issn | 1052-0295 | |
| dc.identifier.issn | 1473-7760 | |
| dc.identifier.issue | 2 | |
| dc.identifier.orcid | 0000-0001-6162-3250 | |
| dc.identifier.orcid | 0000-0001-5702-1847 | |
| dc.identifier.pmid | 36281766 | |
| dc.identifier.scopus | 2-s2.0-85141192470 | |
| dc.identifier.scopusquality | Q2 | |
| dc.identifier.startpage | 140 | |
| dc.identifier.uri | https://doi.org/10.1080/10520295.2022.2135763 | |
| dc.identifier.uri | https://hdl.handle.net/11508/49501 | |
| dc.identifier.volume | 98 | |
| dc.identifier.wos | WOS:000871800200001 | |
| dc.identifier.wosquality | Q4 | |
| dc.indekslendigikaynak | Web of Science | |
| dc.indekslendigikaynak | Scopus | |
| dc.indekslendigikaynak | PubMed | |
| dc.language.iso | en | |
| dc.publisher | Taylor & Francis Ltd | |
| dc.relation.ispartof | Biotechnic & Histochemistry | |
| dc.relation.publicationcategory | Makale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı | |
| dc.rights | info:eu-repo/semantics/closedAccess | |
| dc.snmz | KA_WoS_20260511 | |
| dc.subject | Asprosin | |
| dc.subject | metrnl | |
| dc.subject | subfatin | |
| dc.subject | meteorin-like protein | |
| dc.subject | serous ovarian cancer | |
| dc.title | Use of asprosin and subfatin for differential diagnosis of serous ovarian tumors | |
| dc.type | Article |







